Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 - Eli Lilly and Co (NYSE:LLY) : vimarsana.com

Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 - Eli Lilly and Co (NYSE:LLY)

Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.

Related Keywords

North Carolina , United States , America , Novo Nordisk , Eli Lilly , Christine Romans , Edgardo Hernandez , Eli Lilly Mounjaro , Rhonda Pacheco , Eli Lilly And Co , Us Lilly Diabetes Obesity Group Vice , Obesity Group Vice President ,